Sinopharm’s COVID-19 vaccine has been approved based on the information submitted by G42 Healthcare, which is the company’s distributor for the Middle East and Africa. Information about it’s stability and manufacturing processes were taken into account, as well as input from various consultants and specialists knowledgeable in vaccines and immunizations. More than 7,700 Bahraini volunteers signed up to participate in the Phase III clinical trials. To read more click here.